Addiction Biology:糖尿病药物的新作用

2015-09-29 佚名 生物谷

瑞典科学家对小鼠和大鼠的一项新的研究表明,一种用于糖尿病和肥胖症的药物,也可以成为治疗酒精依赖的有益的工具。这项研究发表在Addict Biology上。 酒精依赖导致发病率和死亡率的上升,是当今社会的主要健康问题。在瑞典,酒精依赖每年造成四千五百万瑞典克朗的经济损失。近5%的瑞典成年人已经被诊断出酒精依赖,这相当于约30万人。甚至更多的瑞典人饮酒过量,例如数据显示15%的人饮酒过量。瑞典哥

瑞典科学家对小鼠和大鼠的一项新的研究表明,一种用于糖尿病和肥胖症的药物,也可以成为治疗酒精依赖的有益的工具。这项研究发表在Addict Biology上。

酒精依赖导致发病率和死亡率的上升,是当今社会的主要健康问题。在瑞典,酒精依赖每年造成四千五百万瑞典克朗的经济损失。近5%的瑞典成年人已经被诊断出酒精依赖,这相当于约30万人。甚至更多的瑞典人饮酒过量,例如数据显示15%的人饮酒过量。瑞典哥德堡大学Sahlgrenska学院的一项新研究表明,干扰一种激素GLP-1的功能,可以被用于治疗酒精依赖,这又是一个完全新的应用。

研究人员发现,一种GLP-1的类似物可以当做药物来治疗酒精依赖。而这种药物以前主要用于治疗2型糖尿病以及肥胖。通常,在饮酒时,多巴胺会在大脑奖励中心释放,导致兴奋感。在小鼠中,GLP-1的类似物可以阻碍饮酒时的多巴胺释放,这意味着他们不会体验到饮酒时的快感。此外,糖尿病药物引起的大鼠的酒精摄入量的减少,以及饮用酒精的动机的消失。而这些大鼠在实验前都有酒精依赖。该药物还可以防止酒精依赖的复发,而这种复发则是酒精依赖者的主要问题之一。

似乎存在酒精依赖和暴饮暴食调节的类似机制。激素GLP-1在小肠释放,这会让我们感觉到饱。它也会在大脑中释放,从而减少食物的摄入量。目前的研究结果表明,GLP-1的生理作用远不止葡萄糖调节和食物摄入量调节,这种激素还影响着酒精摄入的调节。利用治疗糖尿病的药物来治疗有酒精依赖的人,或许会是个不错的选择,最起码药物的安全性可以得到保障,副作用也会相对明确。

原文出处:

Daniel Vall, Paola Maccioni,et al.The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents.Addiction Biology.2015


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858629, encodeId=4f821858629a9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Mar 19 01:17:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917194, encodeId=4af6191e1941d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 13 13:17:00 CST 2016, time=2016-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924130, encodeId=1937192413057, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Mar 25 17:17:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766966, encodeId=52981e66966cb, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun May 22 11:17:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779052, encodeId=1f2f1e7905271, content=<a href='/topic/show?id=726c1965cd' target=_blank style='color:#2F92EE;'>#Addiction#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1965, encryptionId=726c1965cd, topicName=Addiction)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Nov 25 04:17:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584072, encodeId=b7c215840e200, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Oct 01 01:17:00 CST 2015, time=2015-10-01, status=1, ipAttribution=)]
    2016-03-19 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858629, encodeId=4f821858629a9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Mar 19 01:17:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917194, encodeId=4af6191e1941d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 13 13:17:00 CST 2016, time=2016-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924130, encodeId=1937192413057, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Mar 25 17:17:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766966, encodeId=52981e66966cb, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun May 22 11:17:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779052, encodeId=1f2f1e7905271, content=<a href='/topic/show?id=726c1965cd' target=_blank style='color:#2F92EE;'>#Addiction#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1965, encryptionId=726c1965cd, topicName=Addiction)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Nov 25 04:17:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584072, encodeId=b7c215840e200, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Oct 01 01:17:00 CST 2015, time=2015-10-01, status=1, ipAttribution=)]
    2016-08-13 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858629, encodeId=4f821858629a9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Mar 19 01:17:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917194, encodeId=4af6191e1941d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 13 13:17:00 CST 2016, time=2016-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924130, encodeId=1937192413057, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Mar 25 17:17:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766966, encodeId=52981e66966cb, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun May 22 11:17:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779052, encodeId=1f2f1e7905271, content=<a href='/topic/show?id=726c1965cd' target=_blank style='color:#2F92EE;'>#Addiction#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1965, encryptionId=726c1965cd, topicName=Addiction)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Nov 25 04:17:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584072, encodeId=b7c215840e200, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Oct 01 01:17:00 CST 2015, time=2015-10-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858629, encodeId=4f821858629a9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Mar 19 01:17:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917194, encodeId=4af6191e1941d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 13 13:17:00 CST 2016, time=2016-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924130, encodeId=1937192413057, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Mar 25 17:17:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766966, encodeId=52981e66966cb, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun May 22 11:17:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779052, encodeId=1f2f1e7905271, content=<a href='/topic/show?id=726c1965cd' target=_blank style='color:#2F92EE;'>#Addiction#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1965, encryptionId=726c1965cd, topicName=Addiction)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Nov 25 04:17:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584072, encodeId=b7c215840e200, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Oct 01 01:17:00 CST 2015, time=2015-10-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858629, encodeId=4f821858629a9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Mar 19 01:17:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917194, encodeId=4af6191e1941d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 13 13:17:00 CST 2016, time=2016-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924130, encodeId=1937192413057, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Mar 25 17:17:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766966, encodeId=52981e66966cb, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun May 22 11:17:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779052, encodeId=1f2f1e7905271, content=<a href='/topic/show?id=726c1965cd' target=_blank style='color:#2F92EE;'>#Addiction#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1965, encryptionId=726c1965cd, topicName=Addiction)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Nov 25 04:17:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584072, encodeId=b7c215840e200, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Oct 01 01:17:00 CST 2015, time=2015-10-01, status=1, ipAttribution=)]
    2015-11-25 liuquan
  6. [GetPortalCommentsPageByObjectIdResponse(id=1858629, encodeId=4f821858629a9, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Mar 19 01:17:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917194, encodeId=4af6191e1941d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Aug 13 13:17:00 CST 2016, time=2016-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924130, encodeId=1937192413057, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Fri Mar 25 17:17:00 CST 2016, time=2016-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766966, encodeId=52981e66966cb, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun May 22 11:17:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779052, encodeId=1f2f1e7905271, content=<a href='/topic/show?id=726c1965cd' target=_blank style='color:#2F92EE;'>#Addiction#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1965, encryptionId=726c1965cd, topicName=Addiction)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Nov 25 04:17:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584072, encodeId=b7c215840e200, content=<a href='/topic/show?id=1f13e6767e9' target=_blank style='color:#2F92EE;'>#糖尿病药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76767, encryptionId=1f13e6767e9, topicName=糖尿病药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5edb17003695, createdName=minhuang75_72521589, createdTime=Thu Oct 01 01:17:00 CST 2015, time=2015-10-01, status=1, ipAttribution=)]

相关资讯

Diabetologia:睡前服用高血压药物可显著降低糖尿病的发病风险

据最新发表于Diabetologia的一项研究表明,睡前而非早上醒来后服用高血压药物可显著降低2型糖尿病的发病风险。

Lancet Diabetes Endocrinol:阿必鲁泰不影响心血管系统的安全

背景:阿必鲁泰作为胰高血糖素样肽-1受体激动剂,是治疗2型糖尿病的新型药物。研究人员进行阿必鲁泰对心血管安全性的meta分析,这是由US食品药物管理局推荐对糖尿病新型治疗药物做出的评估分析。方法:研究人员对随机应用阿必鲁泰,安慰剂或者其他降糖药物(格列美脲,甘精胰岛素,赖脯胰岛素,利拉鲁肽,匹格列酮,西他列汀)而进行的临床试验进行meta分析,其中八个3期临床试验,一个2b期临床试验。共有患者51

Diabetes Care:有无血管疾病的2型糖尿病患者HbA1c与心血管事件的关系

目标:2型糖尿病患者的血管事件与血糖控制不良相关,但是血管疾病的存在可能影响两者之间的关系。研究人员评估血糖控制(HbA1c)与有无血管疾病的2型糖尿病患者新发心血管事件及其死亡率的关系。研究设计和方法:在SMART的研究中选取2型糖尿病患者1687名,应用Cox比例风险模型,对有无血管疾病进行分层分析HbA1c与心血管事件(包括心肌梗死,卒中以及血管性死亡)发生之间的关系。结果:随访时间的中位数

NEJM:依帕列净能下降2型糖尿病患者心血管事件和死亡率

背景:依帕列净是一种纳葡萄糖共转运体2抑制剂,将其应用在标准化治疗中,对2型糖尿病患者心血管事件的发生率和死亡率的影响尚不清楚。 方法:研究人员随机将患者分为三组,分别给予每天一次10 mg依帕列净,25 mg依帕列净  ,安慰剂。主要的预后是心血管疾病所致死亡,非致命性心肌梗死,非致命性卒中,分析依帕列净组与安慰剂组。主要的次级预后是主要预后加上因不稳定性心绞痛住院。结果:共有7020

糖尿病增加清晨高血压、夜间非杓型血压

大量研究已证实,清晨高血压(HTN)和夜间非杓型(ND)与靶器官损害及心血管事件紧密相关。 近日,《高血压研究》(Hypertension Research)杂志发表的一项研究评估了清晨HTN、ND与肾小球滤过率估计值(eGFR)、蛋白尿的关系,根据是否患糖尿病和慢性肾脏病期数确定清晨HTN、ND的风险。 研究共纳入1312例患者,包括439例糖尿病患者,招募自韩国21个医疗中心。

Eur J Public Health:根据糖尿病治疗指南治疗后的心血管事件风险

背景:坚持根据糖尿病治疗的推荐指南进行治疗,能显著减少患者因心血管疾病住院和死亡的风险。这篇研究的主要目的是评估是否标准化治疗糖尿病能够预测急性心肌梗死(AMI),缺血性卒中(IS),充血性心衰(CHF),下肢截肢(LEA)或以上重大不良心血管事件(MACE)后患者首次住院或死亡的风险,男女之间是否一致?方法:招募2006年91826名(男性46167/女性45659名)住在托斯卡纳区(意大利)的